Gsk (GLAXF) EBT (2009 - 2026)

Gsk's EBT history runs 18 years deep, the most recent figure standing at $2.9 billion for Q1 2026.

• In Q1 2026, EBT rose 8.87% year-over-year to $2.9 billion; the TTM figure through Mar 2026 stood at $10.0 billion (up 20.55% YoY), while the FY2025 annual figure was $9.8 billion, up 119.56% from the prior year.
• EBT was $2.9 billion for Q1 2026 at Gsk, up from $1.3 billion in the prior quarter.
• In the past five years, EBT ranged from a high of $4.8 billion in Q4 2023 to a low of $83.2 million in Q3 2024.
• Historically, EBT has averaged $2.4 billion across 5 years, with a median of $2.5 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: EBT slumped 96.33% in 2024, then soared 3885.36% in 2025.
• A 5-year view of EBT shows it stood at $3.5 billion in 2022, then surged by 37.81% to $4.8 billion in 2023, then retreated by 24.31% to $3.7 billion in 2024, then sank by 65.45% to $1.3 billion in 2025, then soared by 128.74% to $2.9 billion in 2026.
• The last three EBT figures came in at $2.9 billion (Q1 2026), $1.3 billion (Q4 2025), and $3.3 billion (Q3 2025), per Business Quant data.